Skip to content

LogicBio Therapeutics, Inc.

CIK 0001664106

← back to feed
Revenue (TTM)
$10.85M
+56.6% YoY Q3 Nov 2022
Net Income (TTM)
−$27.67M
−22.7% YoY Q3 Nov 2022
EPS Diluted (TTM)
−$0.97
Q3 Nov 2022
Gross Margin
—
Q3 Nov 2022
Operating Margin
-249.1%
Q3 Nov 2022
Net Margin
-254.9%
Q3 Nov 2022
Free Cash Flow (TTM)
−$34.15M
Q3 Nov 2022
Cash
$30.78M
Q3 Nov 2022
Total Debt
$5.93M
Q3 Nov 2022
Shares Outstanding
32.96M sh
Q3 Nov 2022

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings